Fulcrum Therapeutics, Inc.

NASDAQ:FULC

Biotechnology

Healthcare
$3.72 +1.71%

+$0.06 today

Market cap
$284.14M
Beta
2.92
P/E (TTM)
-3.6
EPS (TTM)
-$1.00
52W Low $2.83High $15.74

Volume 0.63M

Average 1.78M

FULC Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Fulcrum Therapeutics, Inc.NASDAQ: FULC

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development growth accelerates

Q1 FY2026 research & development of $14.08M rose 5.1% year over year, ahead of the +0.2% change in trailing-twelve-month research & development. Sequentially, it fell 8.6% from the prior quarter. Over 3 fiscal years it compounded at -9.9% a year.

Context

  • Research & development increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +5.1% holds above the trailing-twelve-month pace of +0.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$14.08M-8.6% QoQ
Last fiscal yearDec 2025
$56.1M-11.5% YoY
LTMMar 2026
$56.78M+0.2% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+5.1%——
1 year-11.5%——
3-year CAGR-9.9%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
56.1M USD
Year-over-year change
-11.5%
4-year CAGR
-5.3%

Research & Development vs competitors

How FULC compares with its peers on the latest reported figures

  • FULC's LTM Mar 2026 research & development of $56.78M is the 7th highest of the 10 companies compared; the peer median is $70.57M.
  • Its year-over-year change of +0.2% is the 6th highest of 10, against a peer median of +16.7%.
  • Over three fiscal years its annual growth of -9.9% compares with a peer median of +8.2%.
FULC Competitors Peer median
Research & Development for FULC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
BCYCBicycle Therapeutics plcLTM Mar 2026$230.13M +16.7%+43.3%362.4%
NMRANeumora Therapeutics, Inc. Common StockLTM Mar 2026$162.51M -21.6%+18.9%—
ADCTADC Therapeutics S.A.LTM Mar 2026$94.95M -15.8%-17.7%119.9%
NGNENeurogene Inc.LTM Mar 2026$82.4M +26.5%+16.4%—
OMEROmeros CorporationLTM Mar 2026$70.57M -39.3%-10.3%713.3%
LXRXLexicon Pharmaceuticals, Inc.LTM Mar 2026$58.28M -31.8%+5.0%83.7%
FULCFulcrum Therapeutics, Inc.LTM Mar 2026$56.78M +0.2%-9.9%—
CMPXCompass Therapeutics, Inc.LTM Mar 2026$56.29M +22.7%+23.1%—
OCGNOcugen, Inc.LTM Mar 2026$41.48M +19.1%-10.9%928.9%
LCTXLineage Cell Therapeutics, Inc.LTM Mar 2026$18.85M +49.9%+8.2%127.5%
Peer median (excluding FULC) $70.57M+16.7%+8.2%245.0%

Competitors are the stored peer set for FULC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue19.16M6.34M2.81M80M0
Cost of Revenue69.7M76.78M71.8M63.39M1.39M
Gross Profit(50.54M)(70.44M)(69M)16.61M(1.39M)
Gross Margin-263.7%-1110.7%-2459.8%20.8%—
Research & Development69.7M76.78M71.8M63.39M56.1M
Selling, General & Admin30.52M41.69M41.67M36.45M28.67M
Operating Expenses30.52M42.12M41.67M38.51M83.38M
Depreciation & Amortization2.52M2.41M2.17M1.59M1.39M
EBITDA(78.33M)(109.72M)(95.16M)(18.24M)(73.49M)
EBITDA Margin-408.8%-1730.1%-3392.6%-22.8%—
Operating Income(81.05M)(112.56M)(110.66M)(21.9M)(84.77M)
Operating Margin-423.0%-1774.9%-3945.2%-27.4%—
Interest Income207K0000
Interest Expense00000
Other Income / Expenses207K2.69M13.33M12.17M9.89M
Income Before Tax(80.85M)(109.87M)(97.34M)(9.73M)(74.88M)
Pre-Tax Margin-421.9%-1732.4%-3470.1%-12.2%—
Income Tax Expense00000
Net Income(80.85M)(109.87M)(97.34M)(9.73M)(74.88M)
Net Margin-421.9%-1732.4%-3470.1%-12.2%—
EPS (Basic)(2.22)(2.35)(1.59)(0.16)(1.18)
EPS (Diluted)(2.22)(2.35)(1.59)(0.16)(1.18)
Weighted Avg Shares35.36M44.99M61.31M61.98M63.36M
Weighted Avg Shares (Diluted)35.36M44.99M61.31M61.98M63.36M

Fulcrum Therapeutics, Inc.

NASDAQ:FULC

Intrinsic Alpha fair value

Locked

Current Price

$3.72

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.